NCT07291063 2025-12-18
Anti-PD-1/PD-L1 Antibodies Plus Gemcitabine and Cisplatin for Advanced CCA
Shanghai Zhongshan Hospital
Recruiting
Clinical Trials
11 trialsNCT07243288 2025-11-21
RADIOPAN
Assistance Publique - Hôpitaux de Paris
Active not recruiting
NCT06893380 2025-09-15
GENTIS
CHA University
Recruiting
NCT03724994 2025-08-29
CHAMP
Lund University
Completed
NCT06975917 2025-05-16
TOG-SAFRADJU
Ankara University
Active not recruiting
NCT06809374 2025-02-05
Investigation of the Optimal Duration of Neoadjuvant Therapy for Resectable Pancreatic Cancer
Kochi University
Completed
NCT04423731 2024-11-20
Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer (NORPACT-2)
Oslo University Hospital
Active not recruiting
NCT02555813 2020-10-19
Treatment of Pancreatic Cancer With Abraxane
Celgene
Completed
NCT04133155 2020-03-13
Retrospective Analysis of 2nd-line Nab-Paclitaxel + Gemcitabine After 1st-line FOLFIRINOX in Pancreatic Cancer
Asan Medical Center
Completed
NCT03668418 2018-09-12
xenoZ
University of Pisa
Unknown
NCT01782690 2018-07-23
An Observational Study of Erlotinib Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Hoffmann-La Roche
Completed